Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.
Here we describe a rapid and direct in vivo CRISPR/Cas9 screening methodology using ultrasound-guided in utero embryonic lentiviral injections to simultaneously assess functions of several genes in the skin and oral cavity of immunocompetent mice.
Genetically modified mouse models (GEMM) have been instrumental in assessing gene function, modeling human diseases, and serving as preclinical model to assess therapeutic avenues. However, their time-, labor- and cost-intensive nature limits their utility for systematic analysis of gene function. Recent advances in genome-editing technologies overcome those limitations and allow for the rapid generation of specific gene perturbations directly within specific mouse organs in a multiplexed and rapid manner. Here, we describe a CRISPR/Cas9-based method (Clustered Regularly Interspaced Short Palindromic Repeats) to generate thousands of gene knock-out clones within the epithelium of the skin and oral cavity of mice, and provide a protocol detailing the steps necessary to perform a direct in vivo CRISPR screen for tumor suppressor genes. This approach can be applied to other organs or other CRISPR/Cas9 technologies such as CRISPR-activation or CRISPR-inactivation to study the biological function of genes during tissue homeostasis or in various disease settings.
One of the challenges for cancer research in the post-genomic era is to mine the vast amount of genome data for causal gene mutations and to identify nodes in the gene network that can be targeted therapeutically. While bioinformatic analyses have helped immensely towards these goals, establishing efficient in vitro and in vivo models is a prerequisite to decipher the complexity of biological systems and disease states and for enabling drug development. While conventional transgenic mouse models have been used extensively for in vivo cancer genetics studies, their cost-, time- and labor-intensive nature has largely prohibited the systematic analysis of the hundreds of putative cancer genes unraveled by modern genomics. To overcome this bottleneck, we combined a previously established ultrasound-guided in utero injection methodology1,2 with a CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing technology3 to simultaneously induce and study loss-of-function mutations of hundreds of genes in skin and oral cavity of a single mouse.
The methodology described here utilizes ultrasound-guided injections of engineered lentiviruses into the amniotic cavity of living mouse embryos at embryonic day E9.5. The lentiviral cargo containing CRISPR/Cas9 components transduce the single-layered surface ectoderm, which later gives rise to the epithelium of the skin and oral cavity. Skin is composed of an outer epidermis, followed by basement membrane and dermis. Epidermis is a stratified epithelium composed of an inner, basal layer, which maintains contact with the basement membrane and has proliferative and stem cell capacity. The basal layer gives rise to the differentiated layers above such as spinous, granular and stratum corneum layers2,4. Lineage tracing studies show that this direct in vivo CRISPR/Cas9 method genetically manipulates tissue-resident stem cells within the basal layer that persist throughout adulthood. As lentivirus can be titrated to transduce the E9.5 surface ectoderm at clonal density, this method can be used to generate mosaic mice harboring thousands of discrete gene knock-out clones. Next generation sequencing can then be used to analyze the effect of CRISPR/Cas9-mediated gene ablation within those clones in a multiplexed manner5.
We recently used this method to assess the function of 484 genes that show recurrent mutations in human Head and Neck Squamous Cell Carcinoma (HNSCC)5. HNSCC is a devastating cancer with a high mortality rate of 40–50% and it is the 6th most common cancer worldwide6. HNSCC arise in mucosal linings of the upper airway or oral cavity and are associated with tobacco and alcohol consumption or human papillomavirus (HPV) infection. Cutaneous Squamous Cell Carcinoma (SCC) are skin tumors and represent the second most common cancer in humans7. Cutaneous SCC and HNSCC are histologically and molecularly very similar, with a high percentage of cases exhibiting alteration in TP53, PIK3CA, NOTCH1, and HRAS8. While there are only a handful of genes mutated at high frequency, there are hundreds of genes found mutated at low frequency (< 5%), a phenomenon commonly referred to as the long-tail distribution. As the majority of the long-tail genes lack biological or clinical validation, we used this in vivo CRISPR screening technology to model loss-of-function of these genes in tumor-prone mice with sensitizing mutations in p53, Pik3ca or Hras and identified several novel tumor suppressor genes that cooperate with p53, Pik3ca or Hras to trigger tumor development5.
Here, we describe a detailed protocol to generate multiplexed sgRNA lentiviral CRISPR sgRNA libraries and perform CRISPR/Cas9 gene knock-out screens in the mouse surface ectoderm. Of note, this methodology can be adapted to incorporate other gene manipulation technologies such as CRISPR activation (CRISPRa) and CRISPR inactivation (CRISPRi) or modified to target other organ systems in mouse to study gene functions.
This protocol was approved and performed in accordance with IACUC of University of Toronto.
1. Design and cloning of pooled CRISPR libraries
2. Production of high titer lentivirus suitable for in vivo transduction
NOTE: Perform all steps in this section of the protocol in a BSL2+ facility in a Class II, Type A2 biosafety cabinet. 293FT and especially the 293NT packaging cells allow for higher virus production. Use low passage (<p20) HEK293T, 293FT or 293NT cells for transfections. Prewarm all media to 37 °C. Never allow HEK293T, 293FT or 293NT cells to become confluent while subculturing. Grow 293FT in the presence of G418 to maintain the expression of the SV40 large T-antigen.
3. Ultra-sound guided surgery and injection
NOTE: This technology was adapted from4,11. Microinjection geared towards transduction of the surface epithelium must be performed at embryonic day E9.5, when the surface ectoderm consists of a single layer and before formation of the periderm starting at E10, which would prevent transduction of this basal layer. Preferably set up mice on Friday, so that the first possible day with E9.5 embryos is the following Monday. Use Rosa26-Lox-STOP-LOX-Cas9-GFP mice (Jackson Laboratory #024857) for optimal CRISPR/Cas9 efficiency12.
4. Deep sequencing procedure
Figure 1A shows the design of the oligonucleotides for multiplexing several custom CRISPR libraries in a cost-effective manner in a single 12k or 92k oligo chip. Once the sgRNAs (blue color coded) are selected, the oligonucleotides are designed with restriction sites (orange colored BsmBI) and library specific PCR primer pairs (green color coded). Several libraries can be designed by using unique combination of primer pairs for multiplexing in a single oligo chip. When PCR amplifying the lib...
CRISPR/Cas9 genome editing has been widely used in in vitro and in vivo studies to investigate gene functions and cellular processes. Most in vivo studies utilize CRISPR/Cas9 gene edited cells grafted into an animal model (allograft or xenograft). While this is a powerful tool to study cancer genetics and cellular functions, it still lacks the native tissue microenvironment and might elicit wounding and/or immune responses.
To overcome these challenges, several groups have pioneered direct in ...
The authors have nothing to disclose.
This work was supported by a project grant from the Canadian Institute of Health Research (CIHR 365252), the Krembil Foundation and the Ontario Research Fund Research Excellence Round 8 (RE08-065). Sampath Kumar Loganathan is the recipient of a Canadian Cancer Society fellowship (BC-F-16#31919).
Name | Company | Catalog Number | Comments |
0.45 micron filter | Sigma | S2HVU02RE | |
12k or 92k oligo chip | Customarray Inc. (Genscript) | ||
15 cm cell culture plates | Corning | ||
293FT | Invitrogen | R70007 | |
293NT | Systems Biosciences | LV900A-1 | |
Alkaline phosphatase | NEB | M0290L | |
Amplicillin | Fisher Scientific | BP1760-25 | |
ATP | NEB | 9804S | |
BsmBI | NEB | R0580L | |
Chromic gut suture | Covidien | ||
Deep sequencing (Next-Seq or Hi-Seq) | Illumina | ||
DNA-cleanup kit | Zymo Research | D4008 | |
DNAesy Blood and Tissue DNA extraction kit | Qiagen | 69506 | |
Endura electrocompetent cells | Lucigen | 60242-1 | |
Glass Capillaries | Drummond | 3-000-203-G/X | |
HEK293T cells | ATCC | CRL-3216 | |
High-Speed Centrifuge | Beckman Coulter | MLS-50 | |
LB Agar | Wisent Technologies | 800-011-LG | |
Micropipette puller | Sutter Instrument | P97 | |
Mineral oil | Sigma | M5904 | |
Mini-prep plasmid Kit | Frogga Bio | PDH300 | |
Mouse oxygen anaesthesia system | Visual Sonics | ||
Nanoject II micromanipulator | Drummond | ||
NEBuffer 3.1 (Buffer for BsmBI) | NEB | R0580L | |
Needle sharpener | Sutter Instrument | BV-10 | |
Oligo cleanup kit | Zymo research | D4060 | |
PAGE purified illumina sequencing primer | IDT DNA | ||
PEI (polyethyleneimine) | Sigma | 408727-100ML | |
Permoplast modeling clay | |||
Petridish with central opening | Visual Sonics | ||
pMD2.G | Addgene | 12259 | |
psPAX2 | Addgene | 12260 | |
Q5 Polymerase 2x Master mix | NEB | M0494L | |
Qubit Fluorometric Quantification | Invitrogen | Q33327 | |
Semicircular Silicone plug | Corning | ||
Silicone membrane | Visual Sonics | ||
T4 DNA ligase | NEB | M0202L | |
Ultra-centrifuge tubes | Beckman Coulter | 344058 | |
Vevo2000 ultrasound system | Visual Sonics |
Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE
Zapytaj o uprawnieniaPrzeglądaj więcej artyków
This article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone